Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Feb 26 2026

0mins

ZLAB+8.13%

Should l Buy ZLAB?

Source: seekingalpha

Significant Revenue Growth: Zai Lab reported total revenue of $127.6 million in Q4 2025, a 17% year-over-year increase, with full-year revenue reaching $460.2 million, up 15%, demonstrating strong performance driven by contributions from XACDURO and NUZYRA.
Rapid R&D Progress: Zoci showed an 80% objective response rate in untreated brain metastases patients with a favorable safety profile, with management emphasizing its advancement to global Phase III trials within two years, targeting U.S. approval by 2028, marking a significant breakthrough in oncology.
Strategic Transition Year: Management views 2026 as a transition year focused on execution and upcoming launches, and while full-year financial guidance was not provided, the expectation is to leverage a robust pipeline and strong cash position to drive long-term growth, reflecting confidence in future market opportunities.
Effective Cost Control: R&D expenses declined by 6% for the full year, while SG&A expenses decreased by 12% in Q4, leading to a 19% improvement in operating loss to $229.4 million, showcasing the company's success in enhancing operational leverage and financial flexibility, strengthening its position in a competitive market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ZLAB?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ZLAB

Wall Street analysts forecast ZLAB stock price to rise

5 Analyst Rating

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 18.810

Low

25.70

Averages

47.93

High

74.00

Current: 18.810

Low

25.70

Averages

47.93

High

74.00

JPMorgan

Anupam Rama

Overweight

downgrade

$39 -> $32

2026-03-18

Reason

JPMorgan

Anupam Rama

Price Target

$39 -> $32

AI Analysis

2026-03-18

downgrade

Overweight

Reason

JPMorgan analyst Anupam Rama lowered the firm's price target on Zai Lab to $32 from $39 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.

Cantor Fitzgerald

Overweight

downgrade

$55 -> $37

2026-02-27

Reason

Cantor Fitzgerald

Price Target

$55 -> $37

2026-02-27

downgrade

Overweight

Reason

Cantor Fitzgerald lowered the firm's price target on Zai Lab to $37 from $55 and keeps an Overweight rating on the shares. Zai Lab reported Q4 and full-year revenues of $127.6M and $460.2M, respectively, in line with consensus, though Vyvgart sales were slightly weaker than expected, the analyst tells investors in a research note. Management indicated that 2026 top-line growth is likely to be modest, with volume gains offset by pricing pressures and competition in China, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZLAB

Unlock Now

About ZLAB

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Zai Lab Partners with Amgen for Global Clinical Trial

9 hours agoseekingalpha

Global Clinical Trial Collaboration: Zai Lab announced a collaboration with Amgen to conduct a global clinical trial studying its antibody-drug conjugate zocilurtatug pelitecan in combination with Amgen's bispecific T-cell engager Imdelltra, marking a strategic move in the small cell lung cancer space.
Clinical Trial Phase: Amgen will sponsor a global Phase 1b study to evaluate the drug combination in patients with extensive-stage small cell lung cancer, which accounts for about two-thirds of SCLC cases, indicating the potential market size of this collaboration.
Ownership and Supply of Drug: Zai Lab will retain full ownership of zocilurtatug pelitecan and supply the experimental therapy for the Amgen-led study, ensuring control over the development process while potentially enhancing its market competitiveness.
Market Outlook for SCLC: Small cell lung cancer accounts for 15% of nearly 2.5 million lung cancer cases diagnosed globally each year, with extensive-stage SCLC having high relapse rates and poor prognosis, highlighting the urgent need for new therapies, and Zai Lab's collaboration aims to address this market gap.

Zai Lab Collaborates with Amgen for Clinical Trial

13 hours agoNewsfilter

Clinical Collaboration Agreement: Zai Lab has entered into a global clinical trial collaboration with Amgen to evaluate the safety and efficacy of DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan in combination with IMDELLTRA®, marking a strategic move in the treatment of small cell lung cancer.
Global Study Launch: Amgen will sponsor a global Phase 1b study while Zai Lab retains full ownership of zocilurtatug pelitecan, which is expected to drive the development of new therapies and enhance the company's competitiveness in the oncology market.
Efficacy Potential: Zocilurtatug pelitecan has demonstrated a high response rate at the EORTC-NCI-AACR and ASCO meetings, particularly showing significant intracranial activity in heavily pretreated small cell lung cancer patients, potentially offering new treatment options for this challenging disease.
Market Outlook: With poor prognosis for small cell lung cancer patients, and IMDELLTRA® already FDA-approved, the combination of zocilurtatug pelitecan and IMDELLTRA® is poised to further improve efficacy, addressing the urgent market demand for new therapies.

Zai Lab Showcases Innovative ADCs at AACR 2026

Mar 17 2026Newsfilter

Drug Presentation: Zai Lab's ADCs ZL-6201 and ZL-1222 will be showcased at the 2026 AACR Annual Meeting, highlighting their potential in treating sarcomas and solid tumors, which is expected to attract investor interest and enhance the company's market profile.
Clinical Trial Progress: Zoci's clinical trials for small cell lung cancer demonstrate promising intracranial responses, with plans for three registration-enabling studies by the end of 2026, potentially establishing it as the first global oncology launch for the company and solidifying its leadership in cancer treatment.
Innovative Treatment Strategy: ZL-6201, as the first LRRC15-targeting ADC, shows promise for multiple solid tumors, potentially transforming existing treatment standards and improving patient survival rates, thereby enhancing the company's market position.
New Direction in Immunotherapy: ZL-1222 aims to overcome PD-1 resistance as a next-generation immunocytokine therapy, enhancing antitumor immunity; if successful, it could open new revenue streams and strengthen the company's competitive edge in the immunotherapy sector.